Global Antihypertensive Drug Market by Drug Category (Diuretics, ACE inhibitors, Angiotensin converting enzyme, Alpha blockers, Beta blockers, Renin inhibitors, Calcium channel blockers and others), Distribution Channel (Hospital, e-commerce, Retail pharmacy) and Region (North America, Europe, Asia-pacific, LAMEA): Global Forecasts 2017 to 2027

The Global antihypertensive drug Market was valued at USD 29.7 billion in 2020, and it is expected to reach USD 34.1 billion by 2027, with a CAGR of 2.1%, during the forecast period (2021-2027).

Antihypertensive Drug Market

Hypertension is one of the most common condition people are facing across the globe. Hypertension is the condition caused by increase in systolic blood pressure on the walls of arteries. Excessive increase in blood pressure case vessels rupture and have high chances of causing serious health issues. The factors that contribute to the growth of antihypertensive drug market are the increase in rate of cardiovascular diseases, kidney failures which are affected by external factors like stress level, work-life balance, diet etc. Increase in geriatric patients has also show effect on the Antihypertensive drug market growth. Due Covid-19, the growth of antihypertensive drug market was hindered due to less cardio-patients and in-patients related to heart diseases.

According to researchers, Age is one of the primary factors that lead to hypertension. It is proved that prevalence of causing hypertension to age group above 60 is higher. Aging is directly proportional to the increase in blood pressure as with age the elastic nature of blood vessels decreases and pressure of blood increases. Therefore, age stood to be important factor for increase in antihypertensive drug market share over period of time.

The government initiative includes the program which will be conducted by Indian Council of Medical Research in collaboration with WHO and Ministry of Health and Family welfare. This will be initiated for providing quality care for hypertension patients of more than 15 crore population for about coming four years and to decrease the number of deaths due to heart failure, Kidney failure. Such awareness camps will help people to understand the seriousness of hypertension and this will ultimately help to increase the market share of antihypertensive drugs and this will affect the growth of antihypertensive drug market.

The Global Antihypertensive Drug Market Segmentation:

By Drug Category type

  • ACE Inhibitors
  • Calcium Channel Blockers
  • Beta-adrenergic Blockers
  • Beta blockers
  • Diuretics
  • Vasodilators
  • Others

By Distribution channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • E-Commerce

By Geographical region

  • North America
  • Europe
  • Asia- Pacific
  • Latin America
  • Middle East and Africa

The unique insights provided by this report also includes the following:

  1. In-depth value chain analysis
  2. Opportunity mapping
  3. Sector snapshot
  4. Key Players Positioning Matrix
  5. Regulatory scenario
  6. Strategies Adopted-Benchmarking Heat Map
  7. Market trends
  8. Covid-19 impact analysis
  9. Product comparison
  10. Pre & Post COVID 19 impacts on antihypertensive drug Market
  11. Competitive Landscape

Based on drug category type, calcium channel blocker drugs are expected to increase the market share of antihypertensive drug and continue to grow with forecast period 2027

Antihypertensive drugs are broadly classified into different categories based on their route of action like calcium channel blockers, alpha blockers, beta blockers, ACE inhibitors etc. The most commonly prescribed drug category is diuretics and calcium channel blockers. As it is researched that, many renal related or kidney problems give rise to hypertension like condition. Moreover, Thiazide diuretics are considered to be one of the most commonly prescribed medication to the patients and this stood to stimulate the Antihypertensive drug market.

A part from diuretics, another most widely prescribed drug category is calcium channel blockers, as it accounts less side effects than other category drugs.

Based on distribution channel, hospital pharmacy is expected to occupy the highest Antihypertensive drug market share

There are different channels of distribution like retail shops, hospital pharmacies and newly e-commerce shops.  As antihypertensive drugs are prescribed drugs, mostly prescribed by the healthcare specialist from the hospitals and this gives rise to increase in market share of drugs through hospital pharmacy channel. On the other side, due to pandemic, e-commerce is expected to have highest market growth rate during forecast period 2021-2027, owing the availability of access of internet across the world.

Based on geographical region, North America dominated the market in 2020 and this is expected to maintain dominance during forecast period.

American Heart Association predicted that there are 75% of American population who are currently undergoing the hypertension treatment and about 53% patients could recover and are under control. They also projected that in coming years by 2030, there will approximately 42% of population to use antihypertensive drugs. North America also has ease supply of antihypertensive drugs which would lead to continue and increase in coming years. Asia- Pacific is expected to show high growth during antihypertensive drug forecast period due to increase in awareness and health consciousness with the populations.

Company Profiles and Competitive Intelligence: Novartis AG (Switzerland), Merck KGaA (Germany), United Therapeutics Corporation (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), Sanofi S.A. (France), AstraZeneca (U.K.), Daiichi Sankyo Company, Ltd. (Japan), Johnson and Johnson Services, Inc. (U.S.), Boehringer Engelheim GmbH (Germany), and Takeda Pharmaceutical Company (Japan)are some of the major players in the global antihypertensive drugs market.

The report also provides in-depth analysis of antihypertensive drug market dynamics such as drivers, restraints opportunities and challenges


  1. Increasing in research and development activities for the novel drugs.
  2. Growing awareness about hypertension, fix dose therapy, and increasing prevalence.


  1. Recent patent expirations of major drugs.
  2. Lack of awareness and low adherence about antihypertensive drug market.


  1. Increase in research related to the antihypertensive drugs is expected to provide lucrative market opportunities during the antihypertensive drug forecast.


  1. Low adherence by patients.
  2. People in developing nations like India ignoring their health-check-ups and not diagnosing until they detect with extreme condition.

COVID-19 Impact on the antihypertensive drug Market Analysis

This covid outbreak has drastically affected the healthcare industry. The measures that were taken to control the cases like lockdown, social distancing led to affect the production and manufacturing of the drugs. There was significant decrease in heart related surgeries, less in patients, and limitation to the hospital consulting; all these factors collectively affected the market share of antihypertensive drugs. Doctors and researchers showed that after some period of time, covid patient’s show complications related to cardiovascular. Looking at this scenario, health care professionals has given permission for the use of cardiovascular drugs irrespective to covid. Hence, there is sudden increase in market of cardiovascular drugs and antihypertensive drug market.

The report also provides in-depth analysis of key trends in Antihypertensive drugs market

Sr. No. Trends Impact
1 Due to Covid-19, there has been very slow growth of hypertensive drug in the market which had poor effect on covid patients. Negative
2 The New drugs in pipeline and inventions impact on antihypertensive drug market Positive

The report also provides in-depth analysis of recent news developments and investments associated with antihypertensive drug market

  • In April 2021, United Therapeutics received an approval from the U.S. FDA and announced about launch of Tyvaso to treat pulmonary hypertension which is associated with interstitial lung disease.
  • In September 2020, the news related to the use of antihypertensive drugs does not appear to increase the risk of cancer, according to the findings of a recent study presented at the European Society of Cardiology (ESC) Congress 2020.


Company Profiles and Competitive Intelligence

The key players operating in the market are:

  1. Merck KGaA (Germany)
  2.  Johnson and Johnson Services, Inc. (U.S.)
  3.  Bayer AG (Germany)
  4. Pfizer Inc. (U.S.),
  5. United Therapeutics Corporation (U.S.)
  6. Sanofi S.A. (France)
  7. Novartis AG (Switzerland)
  8.  AstraZeneca (U.K.)
  9.  Takeda Pharmaceutical Company (Japan)

Frequently Asked Questions (FAQs)

Few key players include, but not limit up to: Merck KGaA (Germany), Johnson and Johnson Services, Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Novartis AG (Switzerland), AstraZeneca (U.K.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Takeda Pharmaceutical Company (Japan).

In the base year 2020, North America accounted for more than 25% share in the antihypertensive drug market

The antihypertensive drug market is estimated to grow at a compound annual growth rate (CAGR) of 2.1% during 2020-2027

The global antihypertensive drug market was valued at US $ 29.7 Mn in 2020 and is anticipated to reach US$ 34.1 Mn by 2027

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

    1. Product Outline
    2. What are Antihypertensive Drugs
    3. Different types of Antihypertensive Drugs
    4. Analysis of Antihypertensive drugs market
    5. Supply Chain Analysis
    6. Covid -19 Impact
    7. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
    8. Technology Overview
    9. Patent Analysis
  2. Technology and Regulatory Landscape for Antihypertensive drugs
    1. Regulations and Standards
  3. Antihypertensive drugs Pricing Analysis
    1. Prices of Antihypertensive drugs
  4.  Antihypertensive drugs by category Type
    1. ACE Inhibitors
    2. Calcium Channel Blockers
    3. Beta-adrenergic Blockers
    4. Beta blockers
    5. Diuretics
    6. Vasodilators
    7. Others
  5. Antihypertensive drugs Market by distribution channel
    1. Hospital Pharmacy
    2. Retail pharmacy
    3. E-commerce
  6. Antihypertensive Drug Market by Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France
      4. Norway
      5. Italy
      6. Spain
      7. Netherlands
      8. Rest Of Europe

6.3  Asia Pacific

6.3.1 China

6.3.2 India

6.3.3 Japan

6.3.4Rest Of Asia Pacific

6.4 Latin America

6.5 Middle East and Africa

  1. Key Strategic Insights of Antihypertensive drug Market
    1. New Raw Material Sources
    2. New Applications
    3. Emerging Technologies
    4. Opportunity mapping
    5. Critical Success Factors
    6. Environmental Impact and sustainability issues
    7. Consumer preferences
  2. Key Market Trends / Recent Developments in Antihypertensive drug market
  3. Competitive Scenario of Antihypertensive drug market
    1. Competitive Strategies of Key Players
      1. Mergers and Acquisitions
      2. Investments
      3. Joint Ventures
      4. New Product launches
    2. Strength of product portfolio
    3. Ranking of Key Players
    4. Presence of players by Geographies

10.1 Merck KGaA (Germany)

10.2 Johnson and Johnson Services, Inc. (U.S.)

10.3 Bayer AG (Germany)

10.4 Pfizer Inc. (U.S.),

10.5 United Therapeutics Corporation (U.S.)

10.6 Sanofi S.A. (France)

10.7 Novartis AG (Switzerland)

10.8 AstraZeneca (U.K.)

10.9 Takeda Pharmaceutical Company (Japan)


Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization